{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-064144","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2026-06-02T20:00:20+00:00","discovered_at":"2026-06-02T20:01:00.682870+00:00","generated_at":"2026-06-02T20:01:12.246613+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"INmune Bio reports statistically significant white matter MRI biomarker in Phase 2 Alzheimer's trial","bullets":["XPro1595 showed significant myelin improvement vs placebo in full mITT (p=0.0028, d=0.46, n=200).","Biomarker-enriched patients (inflammation) showed stronger effect (p=0.0098, d=0.59, n=100).","FDA granted Fast Track designation on May 14, 2026; End-of-Phase 2 alignment secured for Phase 2b/3.","No ARIA-E or ARIA-H observed; favorable safety profile differentiates from amyloid-targeting therapies.","Complete dataset to be presented at AAIC 2026 (July 12-15, London)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-064144","json":"https://secwatch.observer/filing/0001213900-26-064144.json","markdown":"https://secwatch.observer/filing/0001213900-26-064144.md","text":"https://secwatch.observer/filing/0001213900-26-064144.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026064144/0001213900-26-064144-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026064144/ea0293325-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T20:01:12.246613+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001193125-26-253897","ticker":"XMTR","company_name":"Xometry, Inc.","filed_at":"2026-06-02T21:26:17+00:00","headline":"Xometry announces public offering of 2.65M shares at $85.00; expected net proceeds $215.2M","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-253897","json":"https://secwatch.observer/filing/0001193125-26-253897.json","markdown":"https://secwatch.observer/filing/0001193125-26-253897.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1657573/000119312526253897/0001193125-26-253897-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1657573/000119312526253897/d109952d8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-026891","ticker":"HYMC","company_name":"HYCROFT MINING HOLDING CORP","filed_at":"2026-06-02T20:31:13+00:00","headline":"Hycroft TRS shows $10B NPV at spot; 51-year mine life with 10.4M oz gold","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026891","json":"https://secwatch.observer/filing/0001493152-26-026891.json","markdown":"https://secwatch.observer/filing/0001493152-26-026891.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1718405/000149315226026891/0001493152-26-026891-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1718405/000149315226026891/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-253580","ticker":"TTI","company_name":"TETRA TECHNOLOGIES INC","filed_at":"2026-06-02T20:26:51+00:00","headline":"TETRA announces $100M common stock offering, Arkansas Bromine Project approved with $220M remaining capex","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-253580","json":"https://secwatch.observer/filing/0001193125-26-253580.json","markdown":"https://secwatch.observer/filing/0001193125-26-253580.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/844965/000119312526253580/0001193125-26-253580-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/844965/000119312526253580/d39009d8k.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-069482","ticker":"CEG","company_name":"Constellation Energy Corp","filed_at":"2026-06-02T20:15:28+00:00","headline":"Constellation Energy secondary offering of 11M shares with concurrent $558M share repurchase","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069482","json":"https://secwatch.observer/filing/0001104659-26-069482.json","markdown":"https://secwatch.observer/filing/0001104659-26-069482.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868275/000110465926069482/0001104659-26-069482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868275/000110465926069482/tm2616531d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001999371-26-011900","ticker":null,"company_name":"CNL Strategic Capital, LLC","filed_at":"2026-06-02T20:04:39+00:00","headline":"Shareholders reject enhanced liquidity plan (25% repurchase); loan amended for equity buybacks","event_type":"other_material","sec_items":["1.01","2.03","5.07","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-26-011900","json":"https://secwatch.observer/filing/0001999371-26-011900.json","markdown":"https://secwatch.observer/filing/0001999371-26-011900.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1684682/000199937126011900/0001999371-26-011900-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1684682/000199937126011900/cnl-8k_052726.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-252718","ticker":"QMCO","company_name":"QUANTUM CORP /DE/","filed_at":"2026-06-02T14:41:23+00:00","headline":"Quantum raises $100M equity, converts all convertible notes to equity; Q4 revenue above guidance","event_type":"other_material","sec_items":["1.01","2.02","2.03","3.02","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-252718","json":"https://secwatch.observer/filing/0001193125-26-252718.json","markdown":"https://secwatch.observer/filing/0001193125-26-252718.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/709283/000119312526252718/0001193125-26-252718-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/709283/000119312526252718/d35173d8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-026761","ticker":"CELC","company_name":"Celcuity Inc.","filed_at":"2026-06-02T12:10:25+00:00","headline":"Gedatolisib doubles PFS vs alpelisib in PIK3CA mutant HR+/HER2- ABC Phase 3 trial","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026761","json":"https://secwatch.observer/filing/0001493152-26-026761.json","markdown":"https://secwatch.observer/filing/0001493152-26-026761.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603454/000149315226026761/0001493152-26-026761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603454/000149315226026761/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001674930-26-000028","ticker":"FLGT","company_name":"Fulgent Genetics, Inc.","filed_at":"2026-06-01T23:07:35+00:00","headline":"Fulgent Genetics reports encouraging Phase 2 data for FID-007 in HNSCC at ASCO 2026","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001674930-26-000028","json":"https://secwatch.observer/filing/0001674930-26-000028.json","markdown":"https://secwatch.observer/filing/0001674930-26-000028.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674930/000167493026000028/0001674930-26-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674930/000167493026000028/flgt-20260601.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}